Float Short %

7.51

Margin Of Safety %

Put/Call OI Ratio

0.04

EPS Next Q Diff

-0.02

EPS Last/This Y

-0.96

EPS This/Next Y

0.53

Price

4.1

Target Price

Analyst Recom

1.08

Performance Q

-17.51

Relative Volume

1.66

Beta

1.3

Ticker: VYGR

18 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2025-12-26	VYGR	4.09	0.03	0.00	6312
2025-12-29	VYGR	4.04	0.03	0.00	6312
2025-12-30	VYGR	3.94	0.03	0.50	6301
2025-12-31	VYGR	3.92	0.03	0.00	6300
2026-01-02	VYGR	4.03	0.03	0.00	6290
2026-01-05	VYGR	4.09	0.03	0.00	6306
2026-01-06	VYGR	4.03	0.03	0.00	6294
2026-01-07	VYGR	4.08	0.03	0.00	6298
2026-01-08	VYGR	4.07	0.03	0.13	6311
2026-01-09	VYGR	4.03	0.03	0.00	6311
2026-01-12	VYGR	3.89	0.03	4.33	6326
2026-01-13	VYGR	4.03	0.03	0.00	6337
2026-01-14	VYGR	4.09	0.03	0.00	6340
2026-01-15	VYGR	3.83	0.03	0.00	6340
2026-01-16	VYGR	3.77	0.03	0.09	6342
2026-01-20	VYGR	3.66	0.04	0.00	3756
2026-01-21	VYGR	3.78	0.04	0.00	3818
2026-01-22	VYGR	4.09	0.04	0.00	3922
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

18 items 1 of 1

18 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2025-12-26	VYGR	4.08	12.9	-	-2.09
2025-12-29	VYGR	4.04	12.9	-	-2.09
2025-12-30	VYGR	3.93	12.9	-	-2.09
2025-12-31	VYGR	3.92	12.9	-	-2.09
2026-01-02	VYGR	4.03	12.9	-	-2.09
2026-01-05	VYGR	4.09	12.9	-	-2.09
2026-01-06	VYGR	4.03	12.9	-	-2.09
2026-01-07	VYGR	4.08	12.9	-	-2.09
2026-01-08	VYGR	4.07	12.9	-	-2.09
2026-01-09	VYGR	4.02	12.9	-	-2.09
2026-01-12	VYGR	3.89	12.9	-	-2.09
2026-01-13	VYGR	4.03	12.9	-	-2.09
2026-01-14	VYGR	4.13	12.9	-	-2.09
2026-01-15	VYGR	3.82	12.9	-	-2.09
2026-01-16	VYGR	3.76	12.9	-	-2.09
2026-01-20	VYGR	3.67	12.9	-	-2.09
2026-01-21	VYGR	3.78	12.9	-	-2.09
2026-01-22	VYGR	4.10	12.9	-	-2.09
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

18 items 1 of 1

18 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2025-12-26	VYGR	-0.27	-4.15	7.42
2025-12-29	VYGR	-0.27	-4.15	7.42
2025-12-30	VYGR	-0.27	-4.15	7.42
2025-12-31	VYGR	-0.27	-4.15	7.42
2026-01-02	VYGR	-0.27	-4.15	7.42
2026-01-05	VYGR	-0.27	-4.15	7.42
2026-01-06	VYGR	-0.27	-4.15	7.42
2026-01-07	VYGR	-0.27	-4.15	7.42
2026-01-08	VYGR	-0.27	-4.15	7.42
2026-01-09	VYGR	-0.27	-4.15	7.42
2026-01-12	VYGR	-0.27	-4.15	7.42
2026-01-13	VYGR	-0.27	-4.15	7.51
2026-01-14	VYGR	-0.27	-4.15	7.51
2026-01-15	VYGR	-0.27	-4.15	7.51
2026-01-16	VYGR	-0.27	-4.15	7.51
2026-01-20	VYGR	-0.27	-4.18	7.51
2026-01-21	VYGR	-0.27	-4.18	7.51
2026-01-22	VYGR	-0.27	-4.18	7.51
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

18 items 1 of 1

Last Quarter Act. EPS

-0.47

Avg. EPS Est. Current Quarter

-0.51

Avg. EPS Est. Next Quarter

-0.49

Insider Transactions

-0.27

Institutional Transactions

-4.18

Beta

1.3

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

71.4

Max Drawdown 5-Year %

-80.5

Target Price

P/E

Forward P/E

PEG

P/S

7.28

P/B

1.03

P/Free Cash Flow

EPS

-2.17

Average EPS Est. Cur. Y

-2.09

EPS Next Y. (Est.)

-1.56

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

-404.85

Relative Volume

1.66

Return on Equity vs Sector %

-84.9

Return on Equity vs Industry %

-69

EPS 1 7Days Diff

EPS 1 30Days Diff

0.01

EBIT Estimation

Voyager Therapeutics, Inc.

Sector: Healthcare

Industry: Biotechnology

Employees: 172

Voyager Therapeutics, Inc., a biotechnology company, focuses on the human genetics for the cure of neurological diseases. The company's lead product candidate is VY7523, an anti-tau antibody program for the treatment of alzheimer's disease (AD). Its product pipeline includes VY1706, a tau silencing gene therapy in preclinical trial for the treatment of alzheimer's disease; SOD1 silencing gene therapy program for treating amyotrophic lateral sclerosis in preclinical trial; and vectorized anti-amyloid antibody early research program for the treatment of AD in preclinical trial. The company is also developing VY-FXN01 for treating friedreich's ataxia; and GBA1 gene replacement program to treat parkinson's disease. In addition, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Ireland Limited; Novartis Pharma AG; and Neurocrine Biosciences, Inc. for the treatment of various other diseases of the central nervous system. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.

stock quote shares VYGR – Voyager Therapeutics, Inc. Stock Price stock today

news today VYGR – Voyager Therapeutics, Inc. stock forecast ,stock prediction 2023 2024 2025

marketwatch VYGR – Voyager Therapeutics, Inc. yahoo finance google finance

stock history VYGR – Voyager Therapeutics, Inc. invest stock market

stock prices VYGR premarket after hours

ticker VYGR fair value insiders trading

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Relative Volume

Beta

Ticker: VYGR

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Last Quarter Act. EPS

Average EPS Est. Cur. Y